Phosphodiesterase Inhibitor Improves Renal Tubulointerstitial Hypoxia of the Diabetic Rat Kidney

Hui-Kyoung Sun1, Yun Mi Lee2, Kum Hyun Han1, Han-Seong Kim3, Seon-Ho Ahn4, and Sang-Youb Han1,2

1Division of Nephrology, Department of Internal Medicine, 2Clinical Research Center, 3Department of Pathology, Ilsan-Paik Hospital, Inje University College of Medicine, Goyang; 4Division of Nephrology, Department of Medicine, Wonkwang University College of Medicine, Iksan, Korea

Background/Aims: Renal hypoxia is involved in the pathogenesis of diabetic nephropathy. Pentoxifyllin (PTX), a non-selective phosphodiesterase inhibitor, is used to attenuate peripheral vascular diseases. To determine whether PTX can improve renal hypoxia, we investigated its effect in the streptozocin (STZ)-induced diabetic kidney.

Methods: PTX (40 mg/kg, PO) was administered to STZ-induced diabetic rats for 8 weeks. To determine tissue hypoxia, we examined hypoxic inducible factor-1α (HIF-1α), heme oxygenase-1 (HO-1), vascular endothelial growth factor (VEGF), and glucose transporter-1 (GLUT-1) levels. We also tested the effect of PTX on HIF-1α in renal tubule cells.

Results: PTX reduced the increased protein creatinine ratio in diabetic rats at 8 weeks. HIF-1α, VEGF, and GLUT-1 mRNA expression increased significantly, and the expression of HO-1 also tended to increase in diabetic rats. PTX significantly decreased mRNA expression of HIF-1α and VEGF at 4 and 8 weeks, and decreased HO-1 and GLUT-1 at 4 weeks. The expression of HIF-1α protein was significantly increased at 4 and 8 weeks in tubules in the diabetic rat kidney. PTX tended to decrease HIF-1α protein expression at 8 weeks. To examine whether PTX had a direct effect on renal tubules, normal rat kidney cells were stimulated with CoCl2 (100 μM), which enhanced HIF-1α mRNA and protein levels under low glucose conditions (5.5 mM). Their expressions were similar even after high glucose (30 mM) treatment. PTX had no effect on HIF-1α expression.

Conclusions: PTX attenuates tubular hypoxia in the diabetic kidney.

Keywords: Cell hypoxia; Diabetic nephropathies; Phosphodiesterase inhibitors

INTRODUCTION

Chronic hypoxia is involved in the pathogenesis of chronic renal injury, such as diabetic nephropathy. Hypoxic injury can induce tubulointerstitial fibrosis and atrophy [1,2]. These tubulointerstitial changes are associated with structural and functional deterioration of the renal vasculature [3-5].

Glomerular and tubular hypoxia may be induced by hyperglycemia or dysregulation of the glomerular arterioles in diabetic nephropathy. Intra-renal oxygen tension decreases in the diabetic kidney, especially in the...
The changes in intrarenal microcirculation are unclear, but oxygen consumption is increased in the diabetic kidney, suggesting its vulnerability to hypoxia [8].

Hypoxia impairs various cellular functions. Hypoxic cells synthesize hypoxia-inducible transcription factors (HIF) and heme oxygenase (HO) to minimize tissue damage. HIF, which is one of the most important hypoxia-related molecules, plays a role in adaptation to a low oxygen supply [9,10]. HIF is produced in response to hypoxia in various renal cell types [11].

Cyclic-3',5'-phosphodiesterase (PDE) degrades cyclic-3',5'-adenosine monophosphate and cyclic 3',5'-guanosine monophosphate affecting their intra- and extra-cellular concentrations [12]. PDE 3 inhibitor improves endothelial function and inflammatory changes in damaged vascular smooth cells stimulated by tumor necrosis factor-alpha [13,14]. The PDE 4 inhibitor rolipram also reduces expression of adhesion molecules, such as P-selectin and E-selectin, which are critical substances in the binding of white blood cells to endothelial cells [15]. In the clinical field, PDE inhibitors are used to treat peripheral vascular and bronchoconstrictive diseases [16,17].

Despite the fact that hypoxia is involved in the pathogenesis of diabetic nephropathy, restoration of renal tubular hypoxia is difficult. Based on the hypothesis that PDE inhibitors may improve renal tubular hypoxia, we investigated whether pentoxifyllin (PTX), a nonselective PDE inhibitor, may attenuate the hypoxic condition in streptozocin (STZ)-induced type 1 diabetic rats.

**METHODS**

**Animal study and experimental design**

Male Sprague-Dawley rats weighing 200-220 g were divided into three groups. Twelve rats in which diabetes mellitus was not induced were used as controls. Diabetes mellitus was induced by intraperitoneal injection of STZ, 65 mg/kg body weight (Sigma-Aldrich, Saint Louis, MO, USA). Diabetic rats (n = 26) were further randomized into a diabetic control group and a treatment group. Diabetes in the rats was confirmed by a > 300 mg/dL tail blood sugar concentration 48 hours after STZ injection. Rats in the PTX group were treated with 40 mg/kg PTX (Sigma-Aldrich). Fourteen of the rats were sacrificed and the remainder were kept for an additional 4 weeks. Six-hour urine was collected using metabolic cages. Then the rats were anesthetized by intraperitoneal injection of sodium pentobarbital (50 mg/kg). The cortex of one kidney in Trizol reagent (Invitrogen, Carlsbad, CA, USA) was stored at -70°C. The other kidney was perfused with normal saline and fixed in 4% paraformaldehyde.

Body and kidney weights were measured upon sacrifice. Blood glucose levels were determined using standard techniques. Urinary protein was measured with a Pierce BCA Protein Assay Kit (Pierce Biotech Inc., Rockford, IL, USA), and then normalized to urine creatinine measured by the Alkaline Picate method.

**Cell culture and experimental design**

Immortalized normal rat kidney (NRK) cells were acquired from the American Tissue Culture Collection (Rockville, MD, USA). These cells were cultured in DMEM (GibCo BRL, Carlsbad, CA, USA), supplemented with 10% heat-inactivated fetal bovine serum (FBS), 100 U/mL penicillin, and 100 mg/mL streptomycin at 37°C in a humidified atmosphere of 95% air and 5% CO2. Then subconfluent cells were cultured in 0.1% FBS for 24 hours before use in experiments. The cells were incubated in 5.5 mM (normal glucose, NG) or 30 mM (high glucose, HG) D-glucose. To induce hypoxia, 100 μM CoCl2 was administered 6 hours prior. Cells were pretreated with PTX 30 minutes before drug treatment. All experimental groups were cultured in triplicate and harvested at 6 and 24 hours for extraction of total RNA and protein.

**Real-time reverse transcriptase-polymerase chain reaction (RT-PCR)**

Total RNA was extracted from renal cortical tissues or cells with Trizol reagent. Total RNA was reverse transcribed into cDNA using cDNA synthesis (Fermentas, Burlington, Canada) and RNA PCR (Applied Biosystems, Carlsbad, CA, USA) kits in a 20 μL mixture containing 0.5 μg RNA, 50 mM KCl, 50 mM Tris/HC1, 4 mM MgCl2, 1 mM of each dNTP, oligo-(dT) primers, 20 units of RNAs inhibitor, and 50 units of MuLV reverse transcriptase. The reaction mixture was incubated for 10 minutes at 37°C, 60 minutes at 42°C, and then heat-
ed at 90°C for 5 minutes in a thermocycler (GeneAmp PCR system 2700, Applied Biosystems). RT-PCR was performed using standard three-step cycling conditions with SYBR Green Mastermix. Primers were designed from the respective gene sequences using the Primer 3 software. The nucleotide sequences of each primer were as follows: HIF-1α (sense 5' ACAGCACATTCA-CAGCTCCCA, anti-sense 5' TGGTGCTACCATGATGCTTGCGcG), HO-1 (sense GTGCCCTGTGATGTCGCT, anti-sense CCTCAAAAGACAGCCCATTTGGT), vascular endothelial growth factor (VEGF; sense AGCCTTGTCAGCGAGAA, anti-sense TAACTCAAGTCTCAGCCT), glucose transporter-1 (GLUT-1; sense AAAACTGACATCTCGGGC, anti-sense TTCTGAGCCATCAAGTCC), glyceraldehyde-3-phosphate dehydrogenase (GAPDH; sense TGACACAC-CAACTGCTTAGC, anti-sense 5'-GGCATGGACTGTG-GTCATGAG-3'). The expression levels of all genes were normalized to that of the housekeeping gene GAPDH.

**Immunohistochemical staining for HIF-1α and HO-1**

For immunohistochemical staining, renal tissue was immediately fixed in 10% neutral buffered formalin, cast in paraffin, and then sliced into 4 μm thick sections. After removal of paraffin in xylene and dehydration in a graded alcohol series, slides were immersed in distilled water. Kidney sections were transferred to a 10 mM citrate buffer solution for antigen retrieval at a pH of 6.0 and then incubated at a sub-boiling temperature for 15 minutes. After washing with water, 3.0% H2O2 was applied for 15 minutes to block endogenous peroxidase. To inhibit nonspecific staining, slides were incubated at room temperature for 1 hour with normal goat serum. The primary antibodies mouse monoclonal anti-human HIF-1α (Chemicon, Billerica, MA, USA, 1:500) and rabbit polyclonal anti-rat HO (Abcam, Cambridge, MA, USA, 1:1,000) were added to the slides followed by overnight incubation at 4°C. Negative control sections were stained under identical conditions by substituting the primary antibody with equivalent concentrations of normal rabbit IgG.

Expression was evaluated by semi-quantitatively grading staining within tubules. In this method, each score reflects changes in the extent rather than in the intensity of staining, and depends on the percentage of the grid field that stains positive. Four scores were awarded: 0, absent or < 25% positive staining; 1, 25-50% positive staining; 2, 50-75%; and 3, > 75% positive staining. The average score of each sample was calculated. Each slide was scored by an observer blinded to the experimental details.

**Western blotting**

Cells were lysed in buffer (150 mM NaCl, 50 mM Tris-HCl, pH 8.0, 1% Triton X-100, 1 mM phenylmethylsulfonylfluoride), and total protein concentrations were quantified using the advanced protein assay reagent (Bio-Rad, Hercules, CA, USA) in a spectrophotometer. An aliquot of 40 μg protein was electrophoresed on 6% or 10% SDS-polyacrylamide gels under denaturing conditions. Then proteins were transferred to polyvinylidene difluoride membranes (Immobilon-P, Millipore, Billerica, MA, USA) for 120 minutes at 250 mA. After blocking in blocking solution (PBS, 0.15% Tween-20, 5% non-fat milk) for 1 hour at room temperature, membranes were hybridized overnight at 4°C using mouse monoclonal anti-human HIF-1α (Chemicon, 1:500), rab-

| Table 1. Biochemical parameters in experimental animals |
|--------------------------------------------------------|
| **Experimental group** | **Ratio** | **Blood glucose, mg/dL** | **Proteinuria, mg/mgCr** |
|-------------------------|-----------|-------------------------|--------------------------|
| **4 wk**                |           |                         |                          |
| Control rats            | 3.07 ± 0.22 | 100.6 ± 5.86            | 6.95 ± 0.38              |
| DM rats                 | 8.28 ± 1.10 | 397.9 ± 52.7            | 12.2 ± 1.46              |
| DM with PTX             | 7.12 ± 0.77 | 443.0 ± 49.8            | 13.3 ± 1.45              |
| **8 wk**                |           |                         |                          |
| Control rats            | 3.21 ± 0.41 | 106.8 ± 5.35            | 7.22 ± 1.24              |
| DM rats                 | 7.46 ± 0.67 | 478.1 ± 31.2            | 13.9 ± 4.81              |
| DM with PTX             | 8.35 ± 1.05 | 480.2 ± 27.1            | 9.88 ± 1.67              |

Values are presented as mean ± SD. DM, diabetes mellitus; PTX, pentoxifyllin.

*Kidney (mg)/body weight (g). p < 0.05, vs. control. *p < 0.05, vs. DM.
bit polyclonal ant-rat HO-1 (Abcam, 1:1,000), and anti-rat β-actin (Abcam, 1:3,000). The membranes were washed four times with PBS-Tween-20, and incubated for 30 minutes at room temperature with horseradish peroxidase-conjugated secondary antibody, diluted to 1:3,000. Specific signals were detected using the enhanced chemiluminescence method (Amersham, Buckinghamshire, UK). Equal protein loading was confirmed by β-actin.

**Statistical analysis**

We used a nonparametric analysis because most variables were not normally distributed, even after logarithmic transformation. The t-test was used to compare groups, and a value of $p < 0.05$ was defined as statistically significant. All statistical analyses were performed using SPSS version 10.0 (SPSS Inc., Chicago, IL, USA). Data are expressed as mean ± standard deviation.
**RESULTS**

**Baseline characteristics of diabetic rats**

Blood glucose concentration and kidney weight were significantly higher in STZ-induced diabetic rats than in control rats at 4 and 8 weeks. The increased blood glucose concentration and kidney weight were unaffected by PTX treatment.

The protein creatinine ratio was significantly higher in diabetic rats than in control rats at 4 and 8 weeks. This increased ratio decreased in diabetic rats after PTX treatment at 8 weeks (13.9 ± 4.61 vs. 9.88 ± 1.67 mg/mgCr; *p* < 0.05) (Table 1).

**Hypoxia-related factor mRNA levels**

HIF-1α, VEGF, and GLUT-1 mRNA levels were significantly higher in diabetic rats; that of HO-1 tended to increase in diabetic rats. PTX significantly decreased both HIF-1α and VEGF mRNA expression at 4 and 8 weeks, and decreased that of HO-1 and GLUT-1 at 4 weeks (Fig. 1).
Immunohistochemical staining for HIF-1α and HO
HIF-1α synthesis in the diabetic rat kidney increased at both 4 and 8 weeks. At 8 weeks, its expression was consistently higher than that in control rats. HO-1 expression was not different compared to control rats. These molecules were expressed mainly in the tubules, not in the glomeruli. PTX tended to decrease HIF-1α protein expression by 36% at 8 weeks (Figs. 2 and 3).

Effect of PTX on CoCl2-stimulated NRK cells
To investigate whether PTX directly affected renal tubules, NRK cells were stimulated with CoCl2 (100 µM), which induced HIF-1α mRNA production under NG conditions. HIF-1α mRNA was also increased under HG conditions. Production was similar even after HG treatment. HG and CoCl2 showed no synergistic effect on HIF-1α. HIF-1α protein showed a similar pattern. HO-1 mRNA production tended to increase in response to CoCl2, and protein expression was similar to mRNA expression (Fig. 4).

DISCUSSION
PTX reduced HIF-1α and VEGF expression, which are upregulated in diabetic rats, but had no direct effect on HIF-1α in NRK cells stimulated with CoCl2 under both NG and HG conditions. These results suggest that PTX attenuates renal hypoxia in the diabetic kidney.

The effect of hyperglycemia on HIF expression is unclear, and depends on cell type. Hyperglycemia inhibits HIF expression, affecting cell survival [18,19]. VEGF is also suppressed by hypoxic stimuli in diabetic rats [20]. However, hyperglycemia itself stimulates hypoxia-related molecules [8]. In the present study, CoCl2 upregulated HIF-1α expression in renal tubule cells, but did not further affect HIF-1α expression after HG stimulation.

Hypoxia plays an important role in the pathogenesis of diabetic nephropathy due to the relative hypoxia induced by peritubular flow disturbance in hyperfiltration induced by hyperglycemia [21-23]. In addition, peritubular capillary damage reduces renal blood flow, subsequently increasing the intrarenal oxygen requirement [7,24]. There have been attempts to improve re-
nal hypoxia using erythropoietin, prolyl hydroxylase inhibitor, and VEGF [25-28]; however, the efficacies of these compounds are not clear. A recent trial directly increased intrarenal HIF and HO expression to reduce renal tubular damage [29].

The renoprotective effect of PTX in diabetic nephropathy is unclear. Although a metaanalysis showed that PDE inhibitor reduces proteinuria in patients with diabetic nephropathy, PTX has not been used in patients with diabetic nephropathy [30]. In animal studies, PDE inhibitors stimulated lipolysis and free fatty acid synthesis, and improved insulin resistance and endothelial dysfunction [14,31,32]. It also affects peripheral and renal blood flow [33,34], suggesting the possibility of attenuating renal tubular blood flow. In the present study, PTX did not influence HIF-1α expression in NRK cells stimulated with CoCl₂ and HG. The mechanism underlying the beneficial effect of PTX in the STZ-induced diabetic kidney seems to be related to improving renal blood flow by attenuating peritubular endothelial dysfunction, rather than having a direct effect. The mechanism underlying the beneficial effect of PTX on renal hypoxia could be confirmed by measuring renal tubular blood flow.

In conclusion, PTX, a peripheral vasodilator, reduced renal hypoxia in diabetic rats. In the future, direct measurements of blood flow will further clarify the effect of PTX.

Conflict of interest

No potential conflict of interest relevant to this article was reported.

Acknowledgments

This work was supported by a 2009 Korean Association of Internal Medicine Research Grant.

REFERENCES

1. Fine LG, Bandyopadhay D, Norman JT. Is there a common mechanism for the progression of different types of renal diseases other than proteinuria? Towards the unifying theme of chronic hypoxia. Kidney Int Suppl 2000;75:S22-S26.
2. Nangaku M. Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure. J Am Soc Nephrol 2006;17:17-25.
3. Bohle A, von Gise H, Mackensen-Haen S, Stark-Jakob B. The obliteration of the postglomerular capillaries and its influence upon the function of both glomeruli and tubuli: functional interpretation of morphologic findings. Klin Wochenschr 1981;59:1043-1051.
4. Kang DH, Joly AH, Oh SW, et al. Impaired angiogenesis in the remnant kidney model. I. Potential role of vascular endothelial growth factor and thrombospondin-1. J Am Soc Nephrol 2001;12:1434-1447.
5. Ohashi R, Kitamura H, Yamanaka N. Peritubular capillary injury during the progression of experimental glomerulonephritis in rats. J Am Soc Nephrol 2000;11:47-56.
6. Palm F, Cederberg J, Hansell P, Liss P, Carlsson PO. Reactive oxygen species cause diabetes-induced decrease in renal oxygen tension. Diabetologia 2003;46:1153-1160.
7. Ries M, Basseau F, Tyndal B, et al. Renal diffusion and BOLD MRI in experimental diabetic nephropathy: blood oxygen level-dependent. J Magn Reson Imaging 2003;17:104-113.
8. Rosenberger C, Khamaisi M, Abassi Z, et al. Adaptation to hypoxia in the diabetic rat kidney. Kidney Int 2008;73:34-42.
9. Epstein FH, Agmon Y, Brezis M. Physiology of renal hypoxia. Ann N Y Acad Sci 1994;718:72-81.
10. Ratcliffe PJ, O’Rourke JF, Maxwell PH, Pugh CW. Oxygen sensing, hypoxia-inducible factor-1 and the regulation of mammalian gene expression. J Exp Biol 1998;201(Pt 8):1153-1162.
11. Rosenberger C, Griethe W, Gruber G, et al. Cellular responses to hypoxia after renal segmental infarction. Kidney Int 2003;64:874-886.
12. Goy MF. cGMP: the wayward child of the cyclic nucleotide family. Trends Neurosci 1991;14:293-299.
13. Nishio Y, Kashiwagi A, Takahara N, Hidaka H, Kikkawa R. Cilostazol, a cAMP phosphodiesterase inhibitor, attenuates the production of monocyte hemoattractant protein-1 in response to tumor necrosis factor-alpha in vascular endothelial cells. Horm Metab Res 1997;29:491-495.
14. Aoki M, Morishita R, Hayashi S, et al. Inhibition of neointimal formation after balloon injury by cilostazol, accompanied by improvement of endothelial dysfunction and induction of hepatocyte growth factor in rat diabetes model. Diabetologia 2001;44:1034-1042.
15. Sanz MJ, Alvarez A, Piqueras L, et al. Ralipiram inhibits leukocyte-endothelial cell interactions in vivo through P- and E-selectin downregulation. Br J Pharmacol 2002;135:1872-1881.
16. Boolell M, Allen MJ, Ballard SA, et al. Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Im-

http://dx.doi.org/10.3904/kjim.2012.27.2.163  http://www.kjim.or.kr
17. Teixeira MM, Gristwood RW, Cooper N, Hellewell PG. Phosphodiesterase (PDE)4 inhibitors: anti-inflammatory drugs of the future? Trends Pharmacol Sci 1997;18:164-171.
18. Thangarajah H, Yao D, Chang EI, et al. The molecular basis for impaired hypoxia-induced VEGF expression in diabetic tissues. Proc Natl Acad Sci U S A 2009;106:13505-13510.
19. Catrina SB, Okamoto K, Pereira T, Brismar K, Poellinger L. Hyperglycemia regulates hypoxia-inducible factor-1alpha protein stability and function. Diabetes 2004;53:3226-3232.
20. Katavetin P, Miyata T, Inagi R, et al. High glucose blunts vascular endothelial growth factor response to hypoxia via the oxidative stress-regulated hypoxia-inducible factor/hypoxia-responsive element pathway. J Am Soc Nephrol 2006;17:1405-1413.
21. Baines A, Ho P. Glucose stimulates O2 consumption, NOS, and Na/H exchange in diabetic rat proximal tubules. Am J Physiol Renal Physiol 2002;283:F286-F293.
22. O’Connor PM, Kett MM, Anderson WP, Evans RG. Renal medullary tissue oxygenation is dependent on both cortical and medullary blood flow. Am J Physiol Renal Physiol 2006;290:F688-F694.
23. Palm F, Ortsater H, Hansell P, Liss P, Carlsson PO. Differentiating between effects of streptozotocin per se and subsequent hyperglycemia on renal function and metabolism in the streptozotocin-diabetic rat model. Diabetes Metab Res Rev 2004;20:452-459.
24. Izuhara Y, Nangaku M, Inagi R, et al. Renoprotective properties of angiotensin receptor blockers beyond blood pressure lowering. J Am Soc Nephrol 2005;16:3631-3641.
25. Ohtomo S, Nangaku M, Izuhara Y, Takizawa S, Strihou CY, Miyata T. Cobalt ameliorates renal injury in an obese, hypertensive type 2 diabetes rat model. Nephrol Dial Transplant 2008;23:1166-1172.
26. Nangaku M, Izuhara Y, Takizawa S, et al. A novel class of prolyl hydroxylase inhibitors induces angiogenesis and exerts organ protection against ischemia. Arterioscler Thromb Vasc Biol 2007;27:2548-2554.
27. Watanabe D, Suzuma K, Matsui S, et al. Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. N Engl J Med 2005;353:782-792.
28. Aragones J, Schneider M, Van Geyte K, et al. Deficiency or inhibition of oxygen sensor Phd1 induces hypoxia tolerance by reprogramming basal metabolism. Nat Genet 2008;40:170-180.
29. Lee SC, Han SH, Li JJ, et al. Induction of heme oxygenase-1 protects against podocyte apoptosis under diabetic conditions. Kidney Int 2009;76:838-848.
30. McCormick BB, Sydor A, Akbari A, Fergusson D, Doucette S, Knoll G. The effect of pentoxifylline on proteinuria in diabetic kidney disease: a meta-analysis. Am J Kidney Dis 2008;52:454-463.
31. Cheung P, Yang G, Boden G. Milrinone, a selective phosphodiesterase 3 inhibitor, stimulates lipolysis, endogenous glucose production, and insulin secretion. Metabolism 2003;52:1496-1500.
32. Chang SA, Cha BY, Yoo SJ, et al. The effect of cilostazol on glucose tolerance and insulin resistance in a rat model of non-insulin dependent diabetes mellitus. Korean J Intern Med 2001;16:87-92.
33. Frampton JE, Brogden RN. Pentoxifylline (oxpentifylline): a review of its therapeutic efficacy in the management of peripheral vascular and cerebrovascular disorders. Drugs Aging 1995;7:480-503.
34. Tanahashi M, Hara S, Yoshida M, Suzuki-Kusaba M, Hisa H, Satoh S. Effects of rolipram and cilostamide on renal functions and cyclic AMP release in anesthetized dogs. J Pharmacol Exp Ther 1999;289:1533-1538.